Drug developer Akebia Therapeutics Inc. said it had signed a co-development and marketing deal worth up to $1 billion with Japan’s Otsuka Holdings Co. Ltd.
Medical startups must successfully mix entrepreneurial knowledge, a STEM-steeped education, and real-life experience to have the type of lasting impact they desire.
Drug developer Neos Therapeutics Inc. said it resubmitted the marketing application for its attention deficit/hyperactivity disorder (ADHD) drug to the U.S. Food and Drug Administration.
Shares of Acadia Pharmaceuticals were soaring after the company announced its mid-stage drug pimavanserin to treat patients with Alzheimer’s disease psychosis hit its trial endpoints.
PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient’s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.
The U.S. Food and Drug Administration said it approved Clovis Oncology Inc.’s ovarian cancer drug.
Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over.
The Japanese government plans to start reviewing drug prices every year – instead of every two years – to try to reduce mounting healthcare costs, government officials with direct knowledge of the decision said.
Ionis Pharmaceuticals Inc. said its rare metabolic disorder drug for severe hypertriglyceridemia met the main goal in a late-stage study.
Big pharma got an early Christmas present after the Obama administration terminated a controversial plan to combat high drug prices.
Mondher Mahjoub, the head of AstraZeneca’s oncology programming, has jumped ship and will now helm France-based Innate Pharma.
Hungarian pharma firm Richter withdrew a marketing application for a biosimilar drug from the EMA in anticipation of a possible negative assessment.
Mylan, which has come under fire for its drug pricing, will sell a generic version of its life-saving EpiPen allergy treatment at a more than 50 percent discount.
Zombies. They are arguably the most popular monsters in pop culture these days, but a synthetic cannabinoid originally developed by Pfizer has been linked to drug overdoses that led some observers to describe the victims as “zombielike.”
Cambridge Biotech Agios Terminates AG-519 for PK Deficiency, But Continues AG-348 For Same Condition
Agios Pharmaceuticals announced that after a verbal notification from the U.S. Food and Drug Administration of a clinical hold on its clinical trial of AG-519, it is withdrawing its investigational new drug (IND) application and halting the program.
Cellectis is ending 2016 on a roll. The company is closing out the year with a series of successful runs of its Phase I candidate for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), UCART123. The runs met cGMP standards.
Novartis is buying privately held drugmaker Ziarco Group for an undisclosed sum to gain access to its investigational eczema medicine.
Merck & Co. was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit over Gilead Sciences’ blockbuster hepatitis C drugs Sovaldi and Harvoni.
Allergan PLC’s Forest Laboratories and Forest Pharmaceuticals units will pay $38 million to settle U.S. charges that it paid physicians to prescribe three medications, the U.S. Justice Department said.